MaxCyte Q3 revenue up 50% to $10.1M; raises FY2021 guidance to at least $33M

MAXCYTE, INC.

2021-Q3 EPS reported -$0.16 revenue$23,742,100

Total revenue $10.1M (+50% YoY); net loss ($2.7M) improved from ($3.1M) prior year.
SPL Program-related revenue $2.0M (record quarter) vs $0.3M YoY; 15 SPL agreements now.
FY2021 revenue guidance raised to at least $33M from prior outlook of >$30M.
Gross margin 91% (up from 89%); cash and equivalents $255.9M as of Sept 30.
James Lovgren appointed SVP Global Marketing; previously VP at Berkeley Lights.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.